

December 13, 2018

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

The National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Dear Sir/ Madam,

Sub: Press Release - SeQuent receives EIR from USDFA for its Analytical Lab at Mangalore

We are pleased to enclose hereby a press release of the Company titled "SeQuent receives EIR from USDFA for its Analytical Lab at Mangalore"

Kindly take the same on record.

Thanking you,

Yours faithfully,
For Sequent Scientific Limited



Krupesh Mehta
Company Secretary

Encl: A/a

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No.E7,Road No. 22, Wagle Industrial Area, Thane (W), Mumbai – 400604, India

Tel: +91 22 41114777 | FAX: +91-22-41114754 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

SeQuent receives EIR from USFDA for its Analytical Lab at Mangalore

Mumbai, December 13, 2018: SeQuent Scientific Limited (SeQuent) announced that its 100% subsidiary SeQuent Research Limited (SRL) has received Establishment Inspection Report (EIR) from USFDA for its state-of-the-art GLP compliant, Analytical and bio analytical services laboratory at Mangalore.

About SeQuent Research Limited

SRL is an ISO 17025, ISO 9001:2008, ISO 14001:2004 certified facility approved by major regulatory authorities such as USFDA, EDQM, WHO and TGA, and operates out of two centers of excellence – Bangalore and Mangalore with a team of nearly 100 Scientists. It caters to the global pharmaceutical industry in the areas of analytical method development, stability, microbiology testing and method validation of pharmaceutical and cosmeceutical products.

Both SRL centers are equipped with comprehensive capability in instrumental analysis, wet laboratory testing & trace element analysis and have a fully compliant LIMS conforming to 21 CFR.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its API facility at Vizag is India's first and only USFDA approved facility for veterinary APIs.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer
Tel: +91 22 4111 4717
tushar.m@sequent.in

Shivangi Bubna

Christensen Investor Relations
Tel : +91 22 4215 0210
sbubna@christensenir.com

Abhishek Singhal

Investor Relations Consultants
abhishek.s@sequent.in

Registered Office

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22,
Wagle Industrial Area, Thane (W), Maharashtra,
India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.